CDSCO-approved targeted therapy expands precision oncology options for patients with RET-driven lung, thyroid, and other advanced solid tumours
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
